TG-C is an allogeneic (donor) cell and gene therapy involving primary human chondrocytes (cartilage cells) and human cell transduced to express the therapeutic growth factor TGF-ß1. TG-C is a combination of the two. It has been developed to treat knee osteoarthritis, and is delivered via one intra-articular injection into the knee.
The U.S. Phase II study for TG-C was designed as a multi-center, double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of TG-C in 100 patients with Grade 3 chronic degenerative joint disease of the knee. The primary efficacy endpoints were the IKDC Subjective Knee Evaluation and VAS. In US P2 study, one injection demonstrated compelling efficacy results for up to 24 months in improvement in pain and function.
View U.S. Clinical Trial
The pivotal program consists of 2 trials:
